↑ Grab this Headline Animator

Introducing the second analytical tool to analyze the Future Competitive...

Research and Markets (http://www.researchandmarkets.com/reports/c23841) has announced the addition of Analytical Tool - Breast Cancer R&D: A Comprehensive Guide 2005 to their offering



This is the second analytical tool to analyze the future competitive situation of breast cancer therapeutics. More updated and extensive, this version pays considerable attention both to the hormone-based therapeutics as well as the new drugs under development. As new data is emerging, for the recent approved aromatase inhibitor, the therapeutic options are about to change. Replacing Tamoxifen, a selective estrogen receptor modulator that has been used for more than 20 years to treat patients with advanced breast cancer. Important aspects, that in turn changes the situation for all investigational drugs, which have to climb over this new barrier to gain regulatory approval. A proof that breast cancer market produces lucrative returns is the near to 50% increase of sales between the year 2003 and 2004 for most of the aromatase inhibitors. Overall combined sales for the top three breast cancer hormone therapies on the market reaching more than $1.8 billion.



"Analytical Tool: Breast Cancer R&D: A Comprehensive Guide" is the ultimate tool for serious players who would like to understand the current competitive field in breast cancer drug development. Those who are victorious in the field plan effectively and change decisively. It provides a complete and systematic description and analysis of the past, present and future efforts in cancer R&D from both industry as well as academic. We have identified structured and defined information necessary to analyze the most candidates currently under development. Our included CD-ROM database contains thousands of records on the issue of R&D and collaborations derived from a multitude of sources, e.g. news releases, company sources, conferences, scientific publications, patents and published interviews etc.



This highly updated database reflects the most recent advances in the field. Enabling you to perform your own specific analysis, go back to the source data for in-depth information and to offer you an opportunity to easily produce tables and graphs of the information suited for your own specific purposes.



Reasons to purchase this Analytical Tool:

-   
This is the only product that provides you with a complete structure of the areas involved in analyzing breast therapeutics.

-   
It identifies and structures most B2B collaborations and industry-academic alliances

-   
It covers close to all areas of cancer therapeutic strategies, you will be able to study areas in conjunction to cancer structured by therapy type, drug effects, mechanisms/targets and combinatory therapies

-   
It enables you to track cutting edge competitive companies, therapies and technologies in the future market

-   
You will save time and money by rapid identification and analysis of competitors and business opportunities.

-   
You will be able to evaluate progress in both established as well as novel treatment strategies competing within the field of cancer drug development in big pharma.



This Analytical Tool includes three parts:

Breast Cancer: The Latest R&D Trends

Basic Platform Report: Breast Cancer

Business Development and R&D Database: Breast Cancer



Example of candidates include:

The complete number of candidate drugs in clinical research for breast cancer, are more than 150, and some of them below are listed below:



Abraxane, Alimta, Arimidex, Aromasin, Avastin, BMS-217380-01, BMS-247550, CAELYX, CCI-779, Faslodex, Femara, Fenretinide, Gleevec, GTI-2040, Herceptin, Iressa, ISIS-2503, Lapatinib, Nolvadex, Sarasar, SDX-105, Tarceva, Theratope Velcade, Zarnestra, Zoladex ZD0473 and many other that are in an earlier stage of development.



Companies Mentioned:

American Bioscience

AnorMED

AstraZeneca

Biomira Inc

Bristol-Myers Squibb

Eli Lilly and Company

Genentech

GlaxoSmithKline

ISIS Pharmaceuticals

Johnson and Johnson

Lorus Therapeutics

McNeil Pharmaceuticals

Merck KgaA

Millennium Pharmaceuticals

NeoRx

Novartis

OSI Pharmaceuticals

Pfizer

Roche

Salmedix,

Schering-Plough

Wyeth



For more information visit http://www.researchandmarkets.com/reports/c23841



Laura Wood

Senior Manager

Research and Markets

Fax: +353 1 4100 980

↑ Grab this Headline Animator

---

This article has been robotically scanned and tagged by Prnewsnow with the following search tags. No human manipulation of these tags take place.
| Products | Jumpions Com | |

---

4902 readers online...

, Local News